financetom
Business
financetom
/
Business
/
Axis Mutual Fund eyes ₹3 lakh crore AUM by March, expects ₹2,500 crore from new fund
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Axis Mutual Fund eyes ₹3 lakh crore AUM by March, expects ₹2,500 crore from new fund
Nov 29, 2023 8:33 AM

Axis Mutual Fund on Wednesday launched a manufacturing fund and has set a target of collecting at least ₹2,500 crore during the offer period. The Axis Bank subsidiary which competes with 44 other players, is also eyeing around ₹3 lakh AUM by the end of this fiscal, given the market rally.

Share Market Live

NSE

The fund house opened the year with an AUM (assets under management) of over ₹2.25 lakh crore. The open-ended equity scheme represents the manufacturing theme and opens for subscription on December 1 and closes on December 15.

The fund will track the Nifty manufacturing index and will be managed by Shreyash Devalkar and Nitin Arora, the company announced in Mumbai.

If 10% of the investment is redeemed/switched within 12 months from the date of allotment there will be no exit load, while for the remaining investments, there will be a 1% charge, B Gop Kumar, managing director & chief executive of the fund house said.

Also Read: For the first time in over a decade, TCS contributes less than half to Tata Group Mcap

On the overall AUM target for the year, Kumar said the growth has been very good for the company and hopes to close the year with ₹2.8-3 lakh crore in AUM driven by SIPs and fixed-income funds.

On the new fund offer, Raghav Iyengar said they have set an internal target of collecting at least ₹2,500 crore during the offer period. Kumar said the fund will endeavour to harness the potential of the country's growing manufacturing theme, which of late has been gaining increased traction.

The fund managers see increased scope for exports to the US and Europe when it comes to capital goods and power section equipment. The country is transitioning rapidly, thanks to significant government impetus, favourable policy frameworks, and improving cost competitiveness, said Ashish Gupta, a chief investment officer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CVS Shares Are Falling Today: What's Going On?
CVS Shares Are Falling Today: What's Going On?
Dec 19, 2024
CVS Health Corporation’s stock is trading lower Thursday amid news of a lawsuit filed by the U.S. Department of Justice against CVS Pharmacy Inc., a subsidiary of CVS Health ( CVS ). Here’s what you need to know. What To Know: The DOJ alleges that CVS violated the Controlled Substances Act by filling unlawful prescriptions for opioid combinations and excessive...
WEC Energy Upsizes Tender Offer for Senior Notes; Shares Rise
WEC Energy Upsizes Tender Offer for Senior Notes; Shares Rise
Dec 19, 2024
12:45 PM EST, 12/19/2024 (MT Newswires) -- WEC Energy Group ( WEC ) shares were up more than 1% in recent trading Thursday, a day after the company said it upsized the cash tender offer for several series of the company's senior debt. The company said it will accept a total of $400 million of its senior notes, up from...
AGCO Issues EPS, Revenue Outlooks for 2025; Shares Fall
AGCO Issues EPS, Revenue Outlooks for 2025; Shares Fall
Dec 19, 2024
12:51 PM EST, 12/19/2024 (MT Newswires) -- AGCO ( AGCO ) said Thursday that it expects 2025 adjusted EPS of $4.00 to $4.50 and net sales of about $9.6 billion, with market share gains seen more than offset by softening demand and ongoing dealer inventory destocking. FactSet consensus for EPS is $6.31 and $10.7 billion for net sales. AGCO (...
Hims & Hers Health Are Falling Today: What's Going On?
Hims & Hers Health Are Falling Today: What's Going On?
Dec 19, 2024
Hims & Hers Health, Inc. ( HIMS ) are trading lower Thursday. The U.S. Food and Drug Administration issued a new decision about tirzepatide injection shortages. Here’s what you need to know. What To Know: The FDA announced today that the shortage of tirzepatide injections, a GLP-1 medication, has been resolved. The shortage began in 2022 due to high demand...
Copyright 2023-2026 - www.financetom.com All Rights Reserved